Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Kymera Therapeutics (KYMR) PT Raised to $41 at B.Riley
November 1, 2024 5:59 AM EDTB.Riley analyst Kalpit Patel raised the price target on Kymera Therapeutics (NASDAQ: KYMR) to $41.00 (from $36.00) while maintaining a Neutral rating.
The analyst comments "Kymera Therapeutics (KYMRNeutral, $41 PT) announced 3Q24 earnings and provided a business update. Patient dosing has commenced for KT-621, the companys STAT6 degrader, with... More
